New genetic research shows why some people develop deadly Huntington's disease earlier than others. The findings could lead to better treatments.

LEXINGTON, Mass. - uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

Could viral infections play a role in Huntington's disease? Research suggests Apolipoprotein B mRNA editing catalytic ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on QURE stock, giving a Buy rating on January 21.Invest with ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

Subtle signs of neurodegeneration can be detected in blood, CSF, and neuroimaging, up to 20 years before the motor symptoms ...

Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...